Oncology Drug Snapshot: Axitinib (Inlyta)

Slideshow

This oncology drug snapshot takes a look at axitinib (Inlyta) for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.

Recent Videos
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Related Content
Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

Fruquintinib/Sintilimab Meets PFS End Point in Advanced or Metastatic RCC

Tim Cortese
March 19th 2025
Article

Fruquintinib plus sintilimab improved PFS, ORR, and DOR compared with axitinib or everolimus monotherapy in RCC in the phase 2/3 FRUSICA-2 trial.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO
March 7th 2025
Podcast

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

FDA Grants Priority Review to TLX250-CDx in Clear Cell RCC Imaging

Russ Conroy
February 26th 2025
Article

Data from the phase 3 ZIRCON study support the biologics license application for TLX250-CDx in clear cell renal cell carcinoma imaging.

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Expanding and Advancing the Future of Renal Cell Carcinoma Treatment

Eric Jonasch, MD
February 3rd 2025
Podcast

Eric Jonasch, MD, believes that the Kidney Cancer Research Consortium may broaden their reach to provide care to many different groups of patients.

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

Top 5 Takeaways for Genitourinary Cancer Care From 2025 ASCO GU

Russ Conroy
February 21st 2025
Article

Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies.

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.

Belzutifan Receives European Approval in Localized/Advanced RCC Indications

Roman Fabbricatore
February 18th 2025
Article

LITESPARK-004 and LITESPARK-005 trial results support the approval of belzutifan in patients with associated localized or advanced clear cell RCC.